Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Wf 1360b
2. Wf 1360c
3. Wf 1360e
4. Wf 1360f
5. Wf-1360
6. Wf1360
1. Antibiotic Wf-1360
2. Wf-1360
3. 90996-54-6
4. Chebi:72590
5. C1v1y784e4
6. Nsc-332598
7. Fr-900216
8. (1s,3s,5r,8s,10s,11r,13r,14e,16r,17r)-10-hydroxy-8-[(2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0(3,5).0(11,13)]henicos-14-ene-6,19-dione
9. (1s,3s,5r,8s,10s,11r,13r,16r,17r,e)-10-hydroxy-8-((2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyloxazol-4-yl)nona-4,6,8-trien-2-yl)-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione
10. Nsc 332598
11. Brn 5692896
12. Unii-c1v1y784e4
13. Nsc332598
14. Rhizoxin [mi]
15. Schembl15955
16. Chembl379989
17. Dtxsid20897515
18. Crc-87/01
19. E-87/010
20. Q10861060
21. (1s,3s,5r,8s,10s,11r,13r,14e,16r,17r)-10-hydroxy-8-[(2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione
22. (1s-(1r*,3r*,5s*,8r*(1r*,2s*,3e,5e,7e),10r*,11s*,13s*,14e,16s*,17s*))-10-hydroxy-8-(2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl)-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo(15.3.1.03,5.011,13)heneicos-14-ene-6,19-dione
23. 4,7,12,18-tetraoxatetracyclo(15.3.1.03,5.011,13)heneicos-14-ene-6,19-dione, 10-hydroxy-8-(2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl)-11,16-dimethyl-, (1s-(1r*,3r*,5s*,8r*(1r*,2s*,3e,5e,7e),10r*,11s*,13s*,14e,16s*,17s*))-
24. 4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]heneicos-14-ene-6,19-dione, 10-hydroxy-8-[(1s,2r,3e,5e,7e)-2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl]-11,16-dimethyl-, (1s,3s,5r,8s,10s,11r,13r,16s,17r)-
25. Hydroxy-[(1s,2r,3e,5e,7e)-2-methoxy-1,3,7-trimethyl-8-(2-methyloxazol-4-yl)octa-3,5,7-trienyl]-dimethyl-[?]dione
| Molecular Weight | 625.7 g/mol |
|---|---|
| Molecular Formula | C35H47NO9 |
| XLogP3 | 5.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 625.32508208 g/mol |
| Monoisotopic Mass | 625.32508208 g/mol |
| Topological Polar Surface Area | 133 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 1210 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 11 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 4 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)
ABOUT THIS PAGE
A Rhizoxin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rhizoxin, including repackagers and relabelers. The FDA regulates Rhizoxin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rhizoxin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rhizoxin supplier is an individual or a company that provides Rhizoxin active pharmaceutical ingredient (API) or Rhizoxin finished formulations upon request. The Rhizoxin suppliers may include Rhizoxin API manufacturers, exporters, distributors and traders.
click here to find a list of Rhizoxin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rhizoxin DMF (Drug Master File) is a document detailing the whole manufacturing process of Rhizoxin active pharmaceutical ingredient (API) in detail. Different forms of Rhizoxin DMFs exist exist since differing nations have different regulations, such as Rhizoxin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rhizoxin DMF submitted to regulatory agencies in the US is known as a USDMF. Rhizoxin USDMF includes data on Rhizoxin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rhizoxin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rhizoxin suppliers with USDMF on PharmaCompass.
Rhizoxin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rhizoxin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rhizoxin GMP manufacturer or Rhizoxin GMP API supplier for your needs.
A Rhizoxin CoA (Certificate of Analysis) is a formal document that attests to Rhizoxin's compliance with Rhizoxin specifications and serves as a tool for batch-level quality control.
Rhizoxin CoA mostly includes findings from lab analyses of a specific batch. For each Rhizoxin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rhizoxin may be tested according to a variety of international standards, such as European Pharmacopoeia (Rhizoxin EP), Rhizoxin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rhizoxin USP).
LOOKING FOR A SUPPLIER?
